Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Interventions
- Drug: AfatinibDrug: CapivasertibDrug: BinimetinibDrug: AdavosertibProcedure: Biospecimen CollectionOther: Cytology Specimen Collection ProcedureDrug: Afatinib DimaleateDrug: DabrafenibDrug: DefactinibDrug: FexagratinibDrug: DasatinibDrug: IpatasertibProcedure: BiopsyDrug: CrizotinibDrug: Dabrafenib MesylateDrug: TaselisibDrug: SapanisertibDrug: PI3K-beta Inhibitor GSK2636771Drug: Defactinib HydrochlorideDrug: PalbociclibBiological: NivolumabDrug: CopanlisibDrug: UlixertinibBiological: Trastuzumab EmtansineDrug: Copanlisib HydrochlorideBiological: RelatlimabProcedure: Computed TomographyDrug: TrametinibBiological: PertuzumabDrug: ErdafitinibProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanDrug: LarotrectinibProcedure: EchocardiographyDrug: OsimertinibBiological: TrastuzumabDrug: Larotrectinib SulfateOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: VismodegibDrug: Sunitinib MalateProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02450123
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 104
- Registration Number
- NCT02446795
- Locations
- 🇮🇹
Ospedale Oncologico Regionale - Centro di Riferimento Oncologico di Basilicata U.O. di Oncologia Medica, Rionero in vulture, Potenza, Italy
🇮🇹Fondazione G. Pascale, Naples, Italy
🇮🇹University Federico II of Naples, Naples, Italy
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Mendus
- Target Recruit Count
- 88
- Registration Number
- NCT02432846
- Locations
- 🇵🇱
Military Institute of Medicine, Warsaw, Poland
🇺🇸Rush University, Chicago, Illinois, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 915
- Registration Number
- NCT02420821
- Locations
- 🇺🇸
Lynn Cancer Institute/Boca Raton Regional Hospital, Boca Raton, Florida, United States
🇺🇸Florida Cancer Specialists - Port Charlotte, Port Charlotte, Florida, United States
🇺🇸Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Cogent Biosciences, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02401815
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸OSU Comprehensive Cancer Center, Columbus, Ohio, United States
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
- Locations
- 🇺🇸
California Pacific Medical Center Research Institute, San Francisco, California, United States
A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 80
- Registration Number
- NCT02398552
- Locations
- 🇨🇳
Tianjin medical university cancer institute & hospital, Tianjin, Tianjin, China
🇨🇳Chinese acadamy of medical science cancer institute & hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen university cancer center, Guangzhou, Guangdong, China
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT02315625
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT02282059
- Locations
- 🇨🇳
The Affiliated Tumour Hospital of Harbin Medical University, Haerbin, Heilongjiang, China
🇨🇳Eastern Theater General Hospital,QinHuai District Medical Area, Nanjing, Jiangsu, China
🇨🇳Air Force Medical University, Xi'an, Shanxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.